3-D Matrix（7777）株式概要スリー・ディー・マトリックス株式会社 自己組織化ペプチド技術の開発・製造・販売を国内外で展開。 詳細7777 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績3/6財務の健全性6/6配当金0/6報酬株価収益率（ 10.8 x） JP市場（ 14.1 x）を下回っています。今年は黒字化を達成 リスク分析JP市場と比較して、過去 3 か月間の株価の変動が非常に大きい高いレベルの非現金収入 過去1年間で株主の希薄化が進んだ すべてのリスクチェックを見る7777 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW491,113 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG491,113 investors already sharing narrativesYour Fair ValueJP¥Current PriceJP¥351.0066.2% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3b68b2016201920222025202620282031Revenue JP¥68.3bEarnings JP¥26.1bAdvancedSet Fair ValueView all narratives3-D Matrix, Ltd. 競合他社HeartseedSymbol: TSE:219AMarket cap: JP¥36.8bPharma Foods InternationalSymbol: TSE:2929Market cap: JP¥17.9bKohjin BioSymbol: TSE:177AMarket cap: JP¥4.4bFuji PharmaSymbol: TSE:4554Market cap: JP¥49.5b価格と性能株価の高値、安値、推移の概要3-D Matrix過去の株価現在の株価JP¥351.0052週高値JP¥793.0052週安値JP¥193.00ベータ0.991ヶ月の変化-20.05%3ヶ月変化-27.93%1年変化78.17%3年間の変化126.45%5年間の変化0.29%IPOからの変化7.59%最新ニュース分析記事 • Jun 183-D Matrix's (TSE:7777) Performance Raises Some QuestionsStrong earnings weren't enough to please 3-D Matrix, Ltd.'s ( TSE:7777 ) shareholders over the last week. Our analysis...Reported Earnings • Jun 12Full year 2026 earnings released: EPS: JP¥34.88 (vs JP¥25.20 loss in FY 2025)Full year 2026 results: EPS: JP¥34.88 (up from JP¥25.20 loss in FY 2025). Revenue: JP¥10.9b (up 57% from FY 2025). Net income: JP¥4.16b (up JP¥6.66b from FY 2025). Profit margin: 38% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.お知らせ • Jun 113-D Matrix, Ltd., Annual General Meeting, Jul 23, 20263-D Matrix, Ltd., Annual General Meeting, Jul 23, 2026.Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improves as stock rises 22%After last week's 22% share price gain to JP¥474, the stock trades at a trailing P/E ratio of 48.7x. Average trailing P/E is 30x in the Biotechs industry in Asia. Total returns to shareholders of 153% over the past three years.お知らせ • May 103-D Matrix, Ltd. to Report Fiscal Year 2026 Results on Jun 11, 20263-D Matrix, Ltd. announced that they will report fiscal year 2026 results on Jun 11, 2026New Risk • Apr 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).最新情報をもっと見るRecent updates分析記事 • Jun 183-D Matrix's (TSE:7777) Performance Raises Some QuestionsStrong earnings weren't enough to please 3-D Matrix, Ltd.'s ( TSE:7777 ) shareholders over the last week. Our analysis...Reported Earnings • Jun 12Full year 2026 earnings released: EPS: JP¥34.88 (vs JP¥25.20 loss in FY 2025)Full year 2026 results: EPS: JP¥34.88 (up from JP¥25.20 loss in FY 2025). Revenue: JP¥10.9b (up 57% from FY 2025). Net income: JP¥4.16b (up JP¥6.66b from FY 2025). Profit margin: 38% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.お知らせ • Jun 113-D Matrix, Ltd., Annual General Meeting, Jul 23, 20263-D Matrix, Ltd., Annual General Meeting, Jul 23, 2026.Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improves as stock rises 22%After last week's 22% share price gain to JP¥474, the stock trades at a trailing P/E ratio of 48.7x. Average trailing P/E is 30x in the Biotechs industry in Asia. Total returns to shareholders of 153% over the past three years.お知らせ • May 103-D Matrix, Ltd. to Report Fiscal Year 2026 Results on Jun 11, 20263-D Matrix, Ltd. announced that they will report fiscal year 2026 results on Jun 11, 2026New Risk • Apr 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥585, the stock trades at a trailing P/E ratio of 58.7x. Average trailing P/E is 41x in the Biotechs industry in Asia. Total returns to shareholders of 257% over the past three years.Valuation Update With 7 Day Price Move • Mar 19Investor sentiment deteriorates as stock falls 34%After last week's 34% share price decline to JP¥470, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 37x in the Biotechs industry in Asia. Total returns to shareholders of 106% over the past three years.Reported Earnings • Mar 13Third quarter 2026 earnings released: EPS: JP¥5.39 (vs JP¥5.66 loss in 3Q 2025)Third quarter 2026 results: EPS: JP¥5.39 (up from JP¥5.66 loss in 3Q 2025). Revenue: JP¥2.54b (up 42% from 3Q 2025). Net income: JP¥653.0m (up JP¥1.24b from 3Q 2025). Profit margin: 26% (up from net loss in 3Q 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.分析記事 • Jan 163-D Matrix, Ltd.'s (TSE:7777) Price Is Right But Growth Is Lacking After Shares Rocket 46%Despite an already strong run, 3-D Matrix, Ltd. ( TSE:7777 ) shares have been powering on, with a gain of 46% in the...New Risk • Dec 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (21% accrual ratio). Minor Risk Shareholders have been diluted in the past year (19% increase in shares outstanding).Reported Earnings • Dec 16Second quarter 2026 earnings released: EPS: JP¥7.96 (vs JP¥0.18 loss in 2Q 2025)Second quarter 2026 results: EPS: JP¥7.96 (up from JP¥0.18 loss in 2Q 2025). Revenue: JP¥2.61b (up 46% from 2Q 2025). Net income: JP¥936.0m (up JP¥954.0m from 2Q 2025). Profit margin: 36% (up from net loss in 2Q 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.分析記事 • Nov 133-D Matrix, Ltd.'s (TSE:7777) Share Price Boosted 27% But Its Business Prospects Need A Lift TooDespite an already strong run, 3-D Matrix, Ltd. ( TSE:7777 ) shares have been powering on, with a gain of 27% in the...分析記事 • Oct 283-D Matrix (TSE:7777) Is Carrying A Fair Bit Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...お知らせ • Oct 203-D Matrix, Ltd. Announces Collaborative Research with Harvard Drives Regenerative Medicine Breakthrough3-D Matrix, Ltd. has been engaged in the development of medical products based on its proprietary self-assembling peptide technology. In the field of regenerative medicine, the Company has been promoting collaborative research with leading academic institutions worldwide. The company announced that the results of joint research with Harvard University, employing the Company's self-assembling peptide "RADA16," was recently published in the internationally renowned scientific journal Science. This publication marks a advancement in addressing fundamental challenges in cardiac regenerative therapy. Conventional transplantation of iPSC-derived cardiomyocytes has been hindered by the occurrence of life-threatening arrhythmias caused by abnormal automaticity (spontaneous contraction) of the transplanted cells. In this study, the company successfully suppressed this arrhythmogenic automaticity through co-administration of the Company's self- assemblingling peptide. Furthermore, using a technology of flexible nanoelectronics, company were the first in the world to visualize how transplanted cells electrically integrate and synchronize with host cardiac tissue. In addition, the study demonstrated that the peptide significantly accelerated the maturation of the transplanted cells, shifting their gene expression profile from a fetal-like to an adult-like state, and markedly enhanced the organization of sarcomeres, the contractile units of cardiomyocytes. In addition, functional vascularization, which was difficult to verify, was clearly confirmed. The transplanted tissue formed functional anastomoses with host vasculature, establishing a stable supply of oxygen and nutrients, which greatly improved cell survival. This technology is expected not only to accelerate the practical application of iPSC-based therapies for heart disease, but also to drive progress in regenerative medicine for various tissues requiring vascularization. This research was conducted within the existing development budget and will have no impact on full-year financial forecast or current mid-term business plan. The Company will continue to collaborate globally with leading academic institutions to contribute to solving unmet medical needs and to bring new medical value to society through innovation in regenerative medicine.お知らせ • Sep 233-D Matrix, Ltd. to Report Q2, 2026 Results on Dec 11, 20253-D Matrix, Ltd. announced that they will report Q2, 2026 results on Dec 11, 2025Reported Earnings • Sep 12First quarter 2026 earnings released: EPS: JP¥6.88 (vs JP¥9.20 loss in 1Q 2025)First quarter 2026 results: EPS: JP¥6.88 (up from JP¥9.20 loss in 1Q 2025). Revenue: JP¥2.19b (up 48% from 1Q 2025). Net income: JP¥765.0m (up JP¥1.55b from 1Q 2025). Profit margin: 35% (up from net loss in 1Q 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.分析記事 • Aug 013-D Matrix, Ltd. (TSE:7777) Surges 25% Yet Its Low P/S Is No Reason For ExcitementDespite an already strong run, 3-D Matrix, Ltd. ( TSE:7777 ) shares have been powering on, with a gain of 25% in the...お知らせ • Jul 113-D Matrix, Ltd. announced that it has received ¥1.103184 billion in funding from CVI Investments, Inc.On July 10, 2025, 3-D Matrix Co., Ltd. closed the transaction.お知らせ • Jul 093-D Matrix, Ltd. to Report Q1, 2026 Results on Sep 11, 20253-D Matrix, Ltd. announced that they will report Q1, 2026 results on Sep 11, 2025Reported Earnings • Jun 14Full year 2025 earnings released: JP¥25.20 loss per share (vs JP¥3.48 loss in FY 2024)Full year 2025 results: JP¥25.20 loss per share (further deteriorated from JP¥3.48 loss in FY 2024). Revenue: JP¥6.93b (up 51% from FY 2024). Net loss: JP¥2.50b (loss widened JP¥2.25b from FY 2024). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Jun 123-D Matrix, Ltd., Annual General Meeting, Jul 24, 20253-D Matrix, Ltd., Annual General Meeting, Jul 24, 2025.分析記事 • Jun 11Improved Revenues Required Before 3-D Matrix, Ltd. (TSE:7777) Stock's 27% Jump Looks Justified3-D Matrix, Ltd. ( TSE:7777 ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...お知らせ • Apr 113-D Matrix, Ltd. to Report Fiscal Year 2025 Results on Jun 12, 20253-D Matrix, Ltd. announced that they will report fiscal year 2025 results on Jun 12, 2025分析記事 • Apr 07Investors Don't See Light At End Of 3-D Matrix, Ltd.'s (TSE:7777) Tunnel And Push Stock Down 32%To the annoyance of some shareholders, 3-D Matrix, Ltd. ( TSE:7777 ) shares are down a considerable 32% in the last...Reported Earnings • Mar 14Third quarter 2025 earnings released: JP¥5.66 loss per share (vs JP¥7.18 loss in 3Q 2024)Third quarter 2025 results: JP¥5.66 loss per share. Revenue: JP¥1.79b (up 56% from 3Q 2024). Net loss: JP¥588.0m (loss widened 5.0% from 3Q 2024).New Risk • Mar 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 37% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.8b free cash flow). Share price has been highly volatile over the past 3 months (9.4% average weekly change). Shareholders have been substantially diluted in the past year (37% increase in shares outstanding).分析記事 • Feb 173-D Matrix, Ltd. (TSE:7777) Surges 27% Yet Its Low P/S Is No Reason For ExcitementDespite an already strong run, 3-D Matrix, Ltd. ( TSE:7777 ) shares have been powering on, with a gain of 27% in the...お知らせ • Jan 173-D Matrix, Ltd. to Report Q3, 2025 Results on Mar 13, 20253-D Matrix, Ltd. announced that they will report Q3, 2025 results on Mar 13, 2025New Risk • Dec 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.8b free cash flow). Share price has been highly volatile over the past 3 months (7.3% average weekly change). Minor Risks Shareholders have been diluted in the past year (30% increase in shares outstanding). Market cap is less than US$100m (JP¥13.7b market cap, or US$87.4m).分析記事 • Dec 193-D Matrix, Ltd.'s (TSE:7777) Price Is Right But Growth Is Lacking After Shares Rocket 33%3-D Matrix, Ltd. ( TSE:7777 ) shareholders would be excited to see that the share price has had a great month, posting...New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (JP¥12.6b market cap, or US$82.1m).Reported Earnings • Dec 13Second quarter 2025 earnings released: JP¥0.18 loss per share (vs JP¥2.08 loss in 2Q 2024)Second quarter 2025 results: JP¥0.18 loss per share (improved from JP¥2.08 loss in 2Q 2024). Revenue: JP¥1.79b (up 77% from 2Q 2024). Net loss: JP¥18.0m (loss narrowed 88% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.お知らせ • Oct 293-D Matrix, Ltd. to Report Q2, 2025 Results on Dec 12, 20243-D Matrix, Ltd. announced that they will report Q2, 2025 results on Dec 12, 2024Reported Earnings • Sep 17First quarter 2025 earnings released: JP¥9.20 loss per share (vs JP¥0.12 profit in 1Q 2024)First quarter 2025 results: JP¥9.20 loss per share (down from JP¥0.12 profit in 1Q 2024). Revenue: JP¥1.49b (up 80% from 1Q 2024). Net loss: JP¥787.0m (down JP¥795.0m from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.分析記事 • Sep 10We Think 3-D Matrix (TSE:7777) Has A Fair Chunk Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...お知らせ • Aug 033-D Matrix, Ltd. to Report Q1, 2025 Results on Sep 12, 20243-D Matrix, Ltd. announced that they will report Q1, 2025 results on Sep 12, 2024New Risk • Jul 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.9b free cash flow). Share price has been highly volatile over the past 3 months (7.3% average weekly change). Minor Risks Shareholders have been diluted in the past year (34% increase in shares outstanding). Market cap is less than US$100m (JP¥14.2b market cap, or US$92.1m).Reported Earnings • Jun 17Full year 2024 earnings released: JP¥3.48 loss per share (vs JP¥40.62 loss in FY 2023)Full year 2024 results: JP¥3.48 loss per share (improved from JP¥40.62 loss in FY 2023). Revenue: JP¥4.59b (up 98% from FY 2023). Net loss: JP¥255.0m (loss narrowed 90% from FY 2023). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.お知らせ • Jun 153-D Matrix, Ltd., Annual General Meeting, Jul 25, 20243-D Matrix, Ltd., Annual General Meeting, Jul 25, 2024.分析記事 • Jun 083-D Matrix, Ltd. (TSE:7777) Doing What It Can To Lift SharesYou may think that with a price-to-sales (or "P/S") ratio of 3.4x 3-D Matrix, Ltd. ( TSE:7777 ) is definitely a stock...お知らせ • May 173-D Matrix, Ltd. to Report Fiscal Year 2024 Results on Jun 13, 20243-D Matrix, Ltd. announced that they will report fiscal year 2024 results on Jun 13, 2024お知らせ • Apr 043-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc.On April 4, 2024, 3-D Matrix, Ltd., closed the transaction.お知らせ • Mar 203-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc.3-D Matrix, Ltd. announced a private placement to issue 260,000 stock acquisition rights at an issue price of ¥87 per stock acquisition right for the gross proceeds of ¥22,620,000 on March 19, 2024. The transaction will include participation from returning investor, CVI Investments, Inc. The company will issue shares through third-party allotment. The transaction has been approved by the board of directors of the company.Reported Earnings • Mar 14Third quarter 2024 earnings released: JP¥7.18 loss per share (vs JP¥27.66 loss in 3Q 2023)Third quarter 2024 results: JP¥7.18 loss per share (improved from JP¥27.66 loss in 3Q 2023). Revenue: JP¥1.15b (up 100% from 3Q 2023). Net loss: JP¥560.0m (loss narrowed 67% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.お知らせ • Mar 013-D Matrix, Ltd. to Report Q3, 2024 Results on Mar 13, 20243-D Matrix, Ltd. announced that they will report Q3, 2024 results on Mar 13, 2024分析記事 • Feb 26Investors Continue Waiting On Sidelines For 3-D Matrix, Ltd. (TSE:7777)You may think that with a price-to-sales (or "P/S") ratio of 3x 3-D Matrix, Ltd. ( TSE:7777 ) is definitely a stock...Reported Earnings • Dec 16Second quarter 2024 earnings released: JP¥2.08 loss per share (vs JP¥2.42 profit in 2Q 2023)Second quarter 2024 results: JP¥2.08 loss per share (down from JP¥2.42 profit in 2Q 2023). Revenue: JP¥1.01b (up 80% from 2Q 2023). Net loss: JP¥147.0m (down 202% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.お知らせ • Nov 133-D Matrix, Ltd. to Report Q2, 2024 Results on Dec 13, 20233-D Matrix, Ltd. announced that they will report Q2, 2024 results on Dec 13, 2023New Risk • Sep 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥4.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥4.6b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (JP¥10.9b market cap, or US$73.5m).お知らせ • Sep 023-D Matrix, Ltd. to Report Q1, 2024 Results on Sep 13, 20233-D Matrix, Ltd. announced that they will report Q1, 2024 results on Sep 13, 2023Reported Earnings • Aug 02Full year 2023 earnings released: JP¥40.62 loss per share (vs JP¥37.19 loss in FY 2022)Full year 2023 results: JP¥40.62 loss per share (further deteriorated from JP¥37.19 loss in FY 2022). Revenue: JP¥2.31b (up 54% from FY 2022). Net loss: JP¥2.45b (loss widened 29% from FY 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.New Risk • Jul 20New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥4.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-JP¥4.6b free cash flow). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (JP¥9.98b market cap, or US$71.6m).New Risk • Jul 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (JP¥10.6b market cap, or US$73.7m).お知らせ • Jun 163-D Matrix, Ltd., Annual General Meeting, Jul 27, 20233-D Matrix, Ltd., Annual General Meeting, Jul 27, 2023.Reported Earnings • Jun 16Full year 2023 earnings released: JP¥40.62 loss per share (vs JP¥37.19 loss in FY 2022)Full year 2023 results: JP¥40.62 loss per share (further deteriorated from JP¥37.19 loss in FY 2022). Revenue: JP¥2.31b (up 54% from FY 2022). Net loss: JP¥2.45b (loss widened 29% from FY 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • May 103-D Matrix, Ltd. to Report Fiscal Year 2023 Results on Jun 14, 20233-D Matrix, Ltd. announced that they will report fiscal year 2023 results on Jun 14, 2023Reported Earnings • Mar 18Third quarter 2023 earnings released: JP¥27.66 loss per share (vs JP¥15.16 loss in 3Q 2022)Third quarter 2023 results: JP¥27.66 loss per share (further deteriorated from JP¥15.16 loss in 3Q 2022). Revenue: JP¥574.0m (up 59% from 3Q 2022). Net loss: JP¥1.70b (loss widened 106% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • Feb 163-D Matrix, Ltd. to Report Q3, 2023 Results on Mar 17, 20233-D Matrix, Ltd. announced that they will report Q3, 2023 results on Mar 17, 2023Reported Earnings • Dec 15Second quarter 2023 earnings released: EPS: JP¥2.42 (vs JP¥9.09 loss in 2Q 2022)Second quarter 2023 results: EPS: JP¥2.42 (up from JP¥9.09 loss in 2Q 2022). Revenue: JP¥561.0m (up 87% from 2Q 2022). Net income: JP¥144.0m (up JP¥589.0m from 2Q 2022). Profit margin: 26% (up from net loss in 2Q 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent External Director Kazuya Shimamura was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 093-D Matrix, Ltd. to Report Q2, 2023 Results on Dec 13, 20223-D Matrix, Ltd. announced that they will report Q2, 2023 results on Dec 13, 2022お知らせ • Oct 193-D Matrix, Ltd. announced that it has received ¥2.059835568 billion in funding from CVI Investments, Inc.On October 17, 2022, 3-D Matrix, Ltd. closed the transaction.お知らせ • Oct 013-D Matrix, Ltd. announced that it expects to receive ¥2.059835568 billion in funding from CVI Investments, Inc.3-D Matrix, Ltd. announced a private placement of 6th unsecured convertible bonds, with a face of ¥100 each, at a price of ¥100 per corporate bond for gross proceeds of ¥2,050,000,000 with stock acquisition rights and 55,256 33rd stock acquisition rights at a price of ¥178 for gross proceeds of ¥9,835,568; for an aggregate gross proceeds of ¥2,059,835,568 on September 30, 2022. The transaction will include participation from returning investor CVI Investments, Inc. The funding will be raised through third-party allotment. The bonds will be convertible at an initial conversion price of ¥371 into 5,525,606 shares from October 17, 2025 to April 17, 2026 and matures on October 22, 2026. The bonds carry interest rate of 2%. The bonds are redeemable. The exercise period for 33rd stock acquisition rights is from October 18, 2022 to October 18, 2027. They carry an initial exercise price of ¥371 each. The transaction has been approved by the board of directors of directors. The transaction is expected to close on October 17, 2022.Reported Earnings • Sep 16First quarter 2023 earnings released: JP¥9.24 loss per share (vs JP¥17.54 loss in 1Q 2022)First quarter 2023 results: JP¥9.24 loss per share (improved from JP¥17.54 loss in 1Q 2022). Revenue: JP¥423.0m (up 24% from 1Q 2022). Net loss: JP¥524.0m (loss narrowed 34% from 1Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • Aug 033-D Matrix, Ltd. to Report Q1, 2023 Results on Sep 14, 20223-D Matrix, Ltd. announced that they will report Q1, 2023 results on Sep 14, 2022Reported Earnings • Aug 03Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: JP¥37.19 loss per share (up from JP¥49.64 loss in FY 2021). Revenue: JP¥1.51b (up 47% from FY 2021). Net loss: JP¥1.89b (loss narrowed 5.9% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 29%. Over the next year, revenue is forecast to grow 79%, compared to a 256% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • Jun 163-D Matrix, Ltd., Annual General Meeting, Jul 28, 20223-D Matrix, Ltd., Annual General Meeting, Jul 28, 2022.Reported Earnings • Jun 15Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: JP¥37.19 loss per share (up from JP¥49.64 loss in FY 2021). Revenue: JP¥1.51b (up 47% from FY 2021). Net loss: JP¥1.89b (loss narrowed 5.9% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 29%. Over the next year, revenue is forecast to grow 79%, compared to a 546% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.お知らせ • May 133-D Matrix, Ltd. to Report Fiscal Year 2022 Results on Jun 14, 20223-D Matrix, Ltd. announced that they will report fiscal year 2022 results on Jun 14, 2022Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent External Director Kazuya Shimamura was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 133-D Matrix, Ltd. announced that it expects to receive ¥1.7650936 billion in funding from CVI Investments, Inc.3-D Matrix, Ltd. announced a private placement of approximately 17,650,936 5th unsecured convertible bonds, with a face of JPY 100 each, at a price of JPY 100 per corporate bond with 40 units of stock acquisition rights for gross proceeds of JPY 1,765,093,600 and 31st stock acquisition rights on April 11, 2022. The funding will be raised through third-party allotment. The transaction is expected to close on April 27, 2022. The stock acquisition rights will be convertible at a initial conversion price of JPY 441 into 4,002,479 shares. The transaction will include participation from returning investor CVI Investments, Inc. The bonds carry interest rate of 2% and have a redemption date of June 5, 2026. The application period for 31st stock acquisition rights is on April 27, 2022. They carry an initial exercise price of JPY 441 each. The transaction has been approved by the board of directors of directors.Reported Earnings • Mar 16Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: JP¥15.16 loss per share (down from JP¥11.52 loss in 3Q 2021). Revenue: JP¥360.0m (up 55% from 3Q 2021). Net loss: JP¥828.0m (loss widened 73% from 3Q 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 8.2%. Over the next year, revenue is forecast to grow 139%, compared to a 2,909% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Reported Earnings • Dec 17Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: JP¥9.09 loss per share (up from JP¥16.66 loss in 2Q 2021). Revenue: JP¥300.0m (up 14% from 2Q 2021). Net loss: JP¥445.0m (loss narrowed 35% from 2Q 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 8.2%. Earnings per share (EPS) missed analyst estimates by 8.2%. Over the next year, revenue is forecast to grow 135%, compared to a 3,108% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Reported Earnings • Sep 18First quarter 2022 earnings released: JP¥17.54 loss per share (vs JP¥11.16 loss in 1Q 2021)The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: JP¥340.0m (up 63% from 1Q 2021). Net loss: JP¥797.0m (loss widened 95% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.お知らせ • Aug 283-D Matrix, Ltd. announced that it has received ¥2.609 billion in funding from CVI Investments, Inc.On August 27, 2021, 3-D Matrix, Ltd. closed the transaction.お知らせ • Aug 123-D Matrix, Ltd. announced that it expects to receive ¥2.609 billion in funding from CVI Investments, Inc.3-D Matrix, Ltd. announced a private placement of approximately 8,000,000 4th unsecured convertible bonds, with a face of JPY 100 each, at a price of JPY 100 per corporate bond with 40 units of stock acquisition rights for gross proceeds of JPY 800,000,000 and 65,000 30th stock acquisition rights for gross proceeds of JPY 14,430,000, for aggregate gross proceeds of JPY 2,609,000 on August 11, 2021. The funding will be raised through third-party allotment. The transaction is expected to close on August 27, 2021. The stock acquisition rights will be convertible at a initial conversion price of JPY 311 into 2,572,347 shares. The transaction will include participation from returning investor CVI Investments, Inc. The bonds carry no interest rate and have a redemption date of October 4, 2025. The application period for 30th stock acquisition rights is from August 30, 2021 to August 29, 2022. They carry an initial exercise price of JPY 280 each. The transaction has been approved by the board of directors of directors.お知らせ • Aug 053-D Matrix, Ltd. (JASDAQ:7777) signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd.3-D Matrix, Ltd. (JASDAQ:7777) signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd. on August 3, 2021. As part of the transaction, 3-D Matrix, Ltd. will transfer patent and license to PURMX Therapeutics Co., Ltd.Reported Earnings • Aug 03Full year 2021 earnings released: JP¥49.64 loss per share (vs JP¥103 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥1.02b (up 52% from FY 2020). Net loss: JP¥2.01b (loss narrowed 35% from FY 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 18Full year 2021 earnings released: JP¥49.64 loss per share (vs JP¥103 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥1.02b (up 52% from FY 2020). Net loss: JP¥2.01b (loss narrowed 35% from FY 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.分析記事 • Apr 223-D Matrix (TYO:7777) Is Carrying A Fair Bit Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Mar 18Third quarter 2021 earnings released: JP¥11.52 loss per share (vs JP¥22.05 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥233.0m (up 23% from 3Q 2020). Net loss: JP¥479.0m (loss narrowed 28% from 3Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.お知らせ • Mar 073-D Matrix, Ltd. to Report Q3, 2021 Results on Mar 16, 20213-D Matrix, Ltd. announced that they will report Q3, 2021 results on Mar 16, 2021分析記事 • Feb 233-D Matrix's (TYO:7777) Shareholders Are Down 68% On Their SharesThe truth is that if you invest for long enough, you're going to end up with some losing stocks. But long term 3-D...Is New 90 Day High Low • Dec 25New 90-day low: JP¥280The company is down 32% from its price of JP¥410 on 25 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.Reported Earnings • Dec 17Second quarter 2021 earnings released: JP¥16.66 loss per shareThe company reported a solid second quarter result with improved revenues and control over expenses, though losses increased. Second quarter 2021 results: Revenue: JP¥263.0m (up 50% from 2Q 2020). Net loss: JP¥679.0m (loss widened 6.6% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Dec 08New 90-day low: JP¥339The company is down 14% from its price of JP¥395 on 09 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period.お知らせ • Dec 053-D Matrix, Ltd. to Report Q2, 2021 Results on Dec 15, 20203-D Matrix, Ltd. announced that they will report Q2, 2021 results on Dec 15, 2020お知らせ • Nov 113-D Matrix, Ltd. announced that it expects to receive ¥216.0702 million in funding from CVI Investments, Inc.3-D Matrix, Ltd. (JASDAQ:7777) announced that it has entered into purchase agreement to issue 561,700 shares at issue price of ¥356 per share for gross proceeds of ¥199,965,200, 55,000 27th stock acquisition rights at issue price of ¥291 per right for gross proceeds of ¥16,105,000, 10,000 28th stock acquisition rights at issue price of ¥10 per right for gross proceeds of ¥100,000; for an aggregate gross proceeds of ¥216,170,200 on November 10, 2020. The transaction includes participation from returning investor, CVI Investments, Inc. The company will raise money through third party allotment. The 27th stock acquisition rights can be exercisable to purchase 5,500,000 shares of the company at an exercise price of ¥356 per share and 28th stock acquisition rights can be exercise to purchase 1,000,000 shares of the company at an exercise price of ¥435 per share. The 27th stock acquisition rights can be exercised from November 27, 2020 to May 26, 2022 and 28th stock acquisition rights can be exercised from November 27, 2020 to November 26, 2024. The company incurred issuance expense of ¥25,000,000 in relation to the transaction. The transaction is expected to close on November 26, 2020. The transaction has been approved by the board of directors of the company.Is New 90 Day High Low • Nov 01New 90-day low: JP¥378The company is down 3.0% from its price of JP¥389 on 03 August 2020. The Japanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.お知らせ • Sep 043-D Matrix, Ltd. to Report Q1, 2021 Results on Sep 14, 20203-D Matrix, Ltd. announced that they will report Q1, 2021 results on Sep 14, 2020株主還元7777JP BiotechsJP 市場7D-1.7%-2.5%-0.9%1Y78.2%-28.4%42.9%株主還元を見る業界別リターン: 7777過去 1 年間で-28.4 % の収益を上げたJP Biotechs業界を上回りました。リターン対市場: 7777過去 1 年間で42.9 % の収益を上げたJP市場を上回りました。価格変動Is 7777's price volatile compared to industry and market?7777 volatility7777 Average Weekly Movement10.9%Biotechs Industry Average Movement8.0%Market Average Movement4.2%10% most volatile stocks in JP Market9.3%10% least volatile stocks in JP Market2.1%安定した株価: 7777の株価は、 JP市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 7777の weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてJPの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2004114Toshi Amanumawww.3d-matrix.co.jpスリー・ディー・マトリックス株式会社 自己組織化ペプチド技術の開発・製造・販売を国内外で展開。再生医療、細胞治療、ドラッグデリバリーシステムなど様々な分野で使用される自己組織化ペプチドハイドロゲル「PuraMatrix」を提供している。同社は2004年に設立され、東京に本社を置いている。もっと見る3-D Matrix, Ltd. 基礎のまとめ3-D Matrix の収益と売上を時価総額と比較するとどうか。7777 基礎統計学時価総額JP¥44.92b収益（TTM）JP¥4.16b売上高(TTM)JP¥10.89b10.8xPER（株価収益率4.1xP/Sレシオ7777 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計7777 損益計算書（TTM）収益JP¥10.89b売上原価JP¥2.31b売上総利益JP¥8.57bその他の費用JP¥4.42b収益JP¥4.16b直近の収益報告Apr 30, 2026次回決算日該当なし一株当たり利益（EPS）32.47グロス・マージン78.74%純利益率38.17%有利子負債／自己資本比率8.8%7777 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/11 02:22終値2026/07/10 00:00収益2026/04/30年間収益2026/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋3-D Matrix, Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Kiyokazu YamazakiIchiyoshi Research Institute Inc.
分析記事 • Jun 183-D Matrix's (TSE:7777) Performance Raises Some QuestionsStrong earnings weren't enough to please 3-D Matrix, Ltd.'s ( TSE:7777 ) shareholders over the last week. Our analysis...
Reported Earnings • Jun 12Full year 2026 earnings released: EPS: JP¥34.88 (vs JP¥25.20 loss in FY 2025)Full year 2026 results: EPS: JP¥34.88 (up from JP¥25.20 loss in FY 2025). Revenue: JP¥10.9b (up 57% from FY 2025). Net income: JP¥4.16b (up JP¥6.66b from FY 2025). Profit margin: 38% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.
お知らせ • Jun 113-D Matrix, Ltd., Annual General Meeting, Jul 23, 20263-D Matrix, Ltd., Annual General Meeting, Jul 23, 2026.
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improves as stock rises 22%After last week's 22% share price gain to JP¥474, the stock trades at a trailing P/E ratio of 48.7x. Average trailing P/E is 30x in the Biotechs industry in Asia. Total returns to shareholders of 153% over the past three years.
お知らせ • May 103-D Matrix, Ltd. to Report Fiscal Year 2026 Results on Jun 11, 20263-D Matrix, Ltd. announced that they will report fiscal year 2026 results on Jun 11, 2026
New Risk • Apr 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).
分析記事 • Jun 183-D Matrix's (TSE:7777) Performance Raises Some QuestionsStrong earnings weren't enough to please 3-D Matrix, Ltd.'s ( TSE:7777 ) shareholders over the last week. Our analysis...
Reported Earnings • Jun 12Full year 2026 earnings released: EPS: JP¥34.88 (vs JP¥25.20 loss in FY 2025)Full year 2026 results: EPS: JP¥34.88 (up from JP¥25.20 loss in FY 2025). Revenue: JP¥10.9b (up 57% from FY 2025). Net income: JP¥4.16b (up JP¥6.66b from FY 2025). Profit margin: 38% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.
お知らせ • Jun 113-D Matrix, Ltd., Annual General Meeting, Jul 23, 20263-D Matrix, Ltd., Annual General Meeting, Jul 23, 2026.
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improves as stock rises 22%After last week's 22% share price gain to JP¥474, the stock trades at a trailing P/E ratio of 48.7x. Average trailing P/E is 30x in the Biotechs industry in Asia. Total returns to shareholders of 153% over the past three years.
お知らせ • May 103-D Matrix, Ltd. to Report Fiscal Year 2026 Results on Jun 11, 20263-D Matrix, Ltd. announced that they will report fiscal year 2026 results on Jun 11, 2026
New Risk • Apr 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥585, the stock trades at a trailing P/E ratio of 58.7x. Average trailing P/E is 41x in the Biotechs industry in Asia. Total returns to shareholders of 257% over the past three years.
Valuation Update With 7 Day Price Move • Mar 19Investor sentiment deteriorates as stock falls 34%After last week's 34% share price decline to JP¥470, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 37x in the Biotechs industry in Asia. Total returns to shareholders of 106% over the past three years.
Reported Earnings • Mar 13Third quarter 2026 earnings released: EPS: JP¥5.39 (vs JP¥5.66 loss in 3Q 2025)Third quarter 2026 results: EPS: JP¥5.39 (up from JP¥5.66 loss in 3Q 2025). Revenue: JP¥2.54b (up 42% from 3Q 2025). Net income: JP¥653.0m (up JP¥1.24b from 3Q 2025). Profit margin: 26% (up from net loss in 3Q 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
分析記事 • Jan 163-D Matrix, Ltd.'s (TSE:7777) Price Is Right But Growth Is Lacking After Shares Rocket 46%Despite an already strong run, 3-D Matrix, Ltd. ( TSE:7777 ) shares have been powering on, with a gain of 46% in the...
New Risk • Dec 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (21% accrual ratio). Minor Risk Shareholders have been diluted in the past year (19% increase in shares outstanding).
Reported Earnings • Dec 16Second quarter 2026 earnings released: EPS: JP¥7.96 (vs JP¥0.18 loss in 2Q 2025)Second quarter 2026 results: EPS: JP¥7.96 (up from JP¥0.18 loss in 2Q 2025). Revenue: JP¥2.61b (up 46% from 2Q 2025). Net income: JP¥936.0m (up JP¥954.0m from 2Q 2025). Profit margin: 36% (up from net loss in 2Q 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
分析記事 • Nov 133-D Matrix, Ltd.'s (TSE:7777) Share Price Boosted 27% But Its Business Prospects Need A Lift TooDespite an already strong run, 3-D Matrix, Ltd. ( TSE:7777 ) shares have been powering on, with a gain of 27% in the...
分析記事 • Oct 283-D Matrix (TSE:7777) Is Carrying A Fair Bit Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
お知らせ • Oct 203-D Matrix, Ltd. Announces Collaborative Research with Harvard Drives Regenerative Medicine Breakthrough3-D Matrix, Ltd. has been engaged in the development of medical products based on its proprietary self-assembling peptide technology. In the field of regenerative medicine, the Company has been promoting collaborative research with leading academic institutions worldwide. The company announced that the results of joint research with Harvard University, employing the Company's self-assembling peptide "RADA16," was recently published in the internationally renowned scientific journal Science. This publication marks a advancement in addressing fundamental challenges in cardiac regenerative therapy. Conventional transplantation of iPSC-derived cardiomyocytes has been hindered by the occurrence of life-threatening arrhythmias caused by abnormal automaticity (spontaneous contraction) of the transplanted cells. In this study, the company successfully suppressed this arrhythmogenic automaticity through co-administration of the Company's self- assemblingling peptide. Furthermore, using a technology of flexible nanoelectronics, company were the first in the world to visualize how transplanted cells electrically integrate and synchronize with host cardiac tissue. In addition, the study demonstrated that the peptide significantly accelerated the maturation of the transplanted cells, shifting their gene expression profile from a fetal-like to an adult-like state, and markedly enhanced the organization of sarcomeres, the contractile units of cardiomyocytes. In addition, functional vascularization, which was difficult to verify, was clearly confirmed. The transplanted tissue formed functional anastomoses with host vasculature, establishing a stable supply of oxygen and nutrients, which greatly improved cell survival. This technology is expected not only to accelerate the practical application of iPSC-based therapies for heart disease, but also to drive progress in regenerative medicine for various tissues requiring vascularization. This research was conducted within the existing development budget and will have no impact on full-year financial forecast or current mid-term business plan. The Company will continue to collaborate globally with leading academic institutions to contribute to solving unmet medical needs and to bring new medical value to society through innovation in regenerative medicine.
お知らせ • Sep 233-D Matrix, Ltd. to Report Q2, 2026 Results on Dec 11, 20253-D Matrix, Ltd. announced that they will report Q2, 2026 results on Dec 11, 2025
Reported Earnings • Sep 12First quarter 2026 earnings released: EPS: JP¥6.88 (vs JP¥9.20 loss in 1Q 2025)First quarter 2026 results: EPS: JP¥6.88 (up from JP¥9.20 loss in 1Q 2025). Revenue: JP¥2.19b (up 48% from 1Q 2025). Net income: JP¥765.0m (up JP¥1.55b from 1Q 2025). Profit margin: 35% (up from net loss in 1Q 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
分析記事 • Aug 013-D Matrix, Ltd. (TSE:7777) Surges 25% Yet Its Low P/S Is No Reason For ExcitementDespite an already strong run, 3-D Matrix, Ltd. ( TSE:7777 ) shares have been powering on, with a gain of 25% in the...
お知らせ • Jul 113-D Matrix, Ltd. announced that it has received ¥1.103184 billion in funding from CVI Investments, Inc.On July 10, 2025, 3-D Matrix Co., Ltd. closed the transaction.
お知らせ • Jul 093-D Matrix, Ltd. to Report Q1, 2026 Results on Sep 11, 20253-D Matrix, Ltd. announced that they will report Q1, 2026 results on Sep 11, 2025
Reported Earnings • Jun 14Full year 2025 earnings released: JP¥25.20 loss per share (vs JP¥3.48 loss in FY 2024)Full year 2025 results: JP¥25.20 loss per share (further deteriorated from JP¥3.48 loss in FY 2024). Revenue: JP¥6.93b (up 51% from FY 2024). Net loss: JP¥2.50b (loss widened JP¥2.25b from FY 2024). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Jun 123-D Matrix, Ltd., Annual General Meeting, Jul 24, 20253-D Matrix, Ltd., Annual General Meeting, Jul 24, 2025.
分析記事 • Jun 11Improved Revenues Required Before 3-D Matrix, Ltd. (TSE:7777) Stock's 27% Jump Looks Justified3-D Matrix, Ltd. ( TSE:7777 ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...
お知らせ • Apr 113-D Matrix, Ltd. to Report Fiscal Year 2025 Results on Jun 12, 20253-D Matrix, Ltd. announced that they will report fiscal year 2025 results on Jun 12, 2025
分析記事 • Apr 07Investors Don't See Light At End Of 3-D Matrix, Ltd.'s (TSE:7777) Tunnel And Push Stock Down 32%To the annoyance of some shareholders, 3-D Matrix, Ltd. ( TSE:7777 ) shares are down a considerable 32% in the last...
Reported Earnings • Mar 14Third quarter 2025 earnings released: JP¥5.66 loss per share (vs JP¥7.18 loss in 3Q 2024)Third quarter 2025 results: JP¥5.66 loss per share. Revenue: JP¥1.79b (up 56% from 3Q 2024). Net loss: JP¥588.0m (loss widened 5.0% from 3Q 2024).
New Risk • Mar 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 37% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.8b free cash flow). Share price has been highly volatile over the past 3 months (9.4% average weekly change). Shareholders have been substantially diluted in the past year (37% increase in shares outstanding).
分析記事 • Feb 173-D Matrix, Ltd. (TSE:7777) Surges 27% Yet Its Low P/S Is No Reason For ExcitementDespite an already strong run, 3-D Matrix, Ltd. ( TSE:7777 ) shares have been powering on, with a gain of 27% in the...
お知らせ • Jan 173-D Matrix, Ltd. to Report Q3, 2025 Results on Mar 13, 20253-D Matrix, Ltd. announced that they will report Q3, 2025 results on Mar 13, 2025
New Risk • Dec 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.8b free cash flow). Share price has been highly volatile over the past 3 months (7.3% average weekly change). Minor Risks Shareholders have been diluted in the past year (30% increase in shares outstanding). Market cap is less than US$100m (JP¥13.7b market cap, or US$87.4m).
分析記事 • Dec 193-D Matrix, Ltd.'s (TSE:7777) Price Is Right But Growth Is Lacking After Shares Rocket 33%3-D Matrix, Ltd. ( TSE:7777 ) shareholders would be excited to see that the share price has had a great month, posting...
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (JP¥12.6b market cap, or US$82.1m).
Reported Earnings • Dec 13Second quarter 2025 earnings released: JP¥0.18 loss per share (vs JP¥2.08 loss in 2Q 2024)Second quarter 2025 results: JP¥0.18 loss per share (improved from JP¥2.08 loss in 2Q 2024). Revenue: JP¥1.79b (up 77% from 2Q 2024). Net loss: JP¥18.0m (loss narrowed 88% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
お知らせ • Oct 293-D Matrix, Ltd. to Report Q2, 2025 Results on Dec 12, 20243-D Matrix, Ltd. announced that they will report Q2, 2025 results on Dec 12, 2024
Reported Earnings • Sep 17First quarter 2025 earnings released: JP¥9.20 loss per share (vs JP¥0.12 profit in 1Q 2024)First quarter 2025 results: JP¥9.20 loss per share (down from JP¥0.12 profit in 1Q 2024). Revenue: JP¥1.49b (up 80% from 1Q 2024). Net loss: JP¥787.0m (down JP¥795.0m from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
分析記事 • Sep 10We Think 3-D Matrix (TSE:7777) Has A Fair Chunk Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
お知らせ • Aug 033-D Matrix, Ltd. to Report Q1, 2025 Results on Sep 12, 20243-D Matrix, Ltd. announced that they will report Q1, 2025 results on Sep 12, 2024
New Risk • Jul 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.9b free cash flow). Share price has been highly volatile over the past 3 months (7.3% average weekly change). Minor Risks Shareholders have been diluted in the past year (34% increase in shares outstanding). Market cap is less than US$100m (JP¥14.2b market cap, or US$92.1m).
Reported Earnings • Jun 17Full year 2024 earnings released: JP¥3.48 loss per share (vs JP¥40.62 loss in FY 2023)Full year 2024 results: JP¥3.48 loss per share (improved from JP¥40.62 loss in FY 2023). Revenue: JP¥4.59b (up 98% from FY 2023). Net loss: JP¥255.0m (loss narrowed 90% from FY 2023). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
お知らせ • Jun 153-D Matrix, Ltd., Annual General Meeting, Jul 25, 20243-D Matrix, Ltd., Annual General Meeting, Jul 25, 2024.
分析記事 • Jun 083-D Matrix, Ltd. (TSE:7777) Doing What It Can To Lift SharesYou may think that with a price-to-sales (or "P/S") ratio of 3.4x 3-D Matrix, Ltd. ( TSE:7777 ) is definitely a stock...
お知らせ • May 173-D Matrix, Ltd. to Report Fiscal Year 2024 Results on Jun 13, 20243-D Matrix, Ltd. announced that they will report fiscal year 2024 results on Jun 13, 2024
お知らせ • Apr 043-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc.On April 4, 2024, 3-D Matrix, Ltd., closed the transaction.
お知らせ • Mar 203-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc.3-D Matrix, Ltd. announced a private placement to issue 260,000 stock acquisition rights at an issue price of ¥87 per stock acquisition right for the gross proceeds of ¥22,620,000 on March 19, 2024. The transaction will include participation from returning investor, CVI Investments, Inc. The company will issue shares through third-party allotment. The transaction has been approved by the board of directors of the company.
Reported Earnings • Mar 14Third quarter 2024 earnings released: JP¥7.18 loss per share (vs JP¥27.66 loss in 3Q 2023)Third quarter 2024 results: JP¥7.18 loss per share (improved from JP¥27.66 loss in 3Q 2023). Revenue: JP¥1.15b (up 100% from 3Q 2023). Net loss: JP¥560.0m (loss narrowed 67% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
お知らせ • Mar 013-D Matrix, Ltd. to Report Q3, 2024 Results on Mar 13, 20243-D Matrix, Ltd. announced that they will report Q3, 2024 results on Mar 13, 2024
分析記事 • Feb 26Investors Continue Waiting On Sidelines For 3-D Matrix, Ltd. (TSE:7777)You may think that with a price-to-sales (or "P/S") ratio of 3x 3-D Matrix, Ltd. ( TSE:7777 ) is definitely a stock...
Reported Earnings • Dec 16Second quarter 2024 earnings released: JP¥2.08 loss per share (vs JP¥2.42 profit in 2Q 2023)Second quarter 2024 results: JP¥2.08 loss per share (down from JP¥2.42 profit in 2Q 2023). Revenue: JP¥1.01b (up 80% from 2Q 2023). Net loss: JP¥147.0m (down 202% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
お知らせ • Nov 133-D Matrix, Ltd. to Report Q2, 2024 Results on Dec 13, 20233-D Matrix, Ltd. announced that they will report Q2, 2024 results on Dec 13, 2023
New Risk • Sep 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥4.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥4.6b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (JP¥10.9b market cap, or US$73.5m).
お知らせ • Sep 023-D Matrix, Ltd. to Report Q1, 2024 Results on Sep 13, 20233-D Matrix, Ltd. announced that they will report Q1, 2024 results on Sep 13, 2023
Reported Earnings • Aug 02Full year 2023 earnings released: JP¥40.62 loss per share (vs JP¥37.19 loss in FY 2022)Full year 2023 results: JP¥40.62 loss per share (further deteriorated from JP¥37.19 loss in FY 2022). Revenue: JP¥2.31b (up 54% from FY 2022). Net loss: JP¥2.45b (loss widened 29% from FY 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
New Risk • Jul 20New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥4.6b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-JP¥4.6b free cash flow). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (JP¥9.98b market cap, or US$71.6m).
New Risk • Jul 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (JP¥10.6b market cap, or US$73.7m).
お知らせ • Jun 163-D Matrix, Ltd., Annual General Meeting, Jul 27, 20233-D Matrix, Ltd., Annual General Meeting, Jul 27, 2023.
Reported Earnings • Jun 16Full year 2023 earnings released: JP¥40.62 loss per share (vs JP¥37.19 loss in FY 2022)Full year 2023 results: JP¥40.62 loss per share (further deteriorated from JP¥37.19 loss in FY 2022). Revenue: JP¥2.31b (up 54% from FY 2022). Net loss: JP¥2.45b (loss widened 29% from FY 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • May 103-D Matrix, Ltd. to Report Fiscal Year 2023 Results on Jun 14, 20233-D Matrix, Ltd. announced that they will report fiscal year 2023 results on Jun 14, 2023
Reported Earnings • Mar 18Third quarter 2023 earnings released: JP¥27.66 loss per share (vs JP¥15.16 loss in 3Q 2022)Third quarter 2023 results: JP¥27.66 loss per share (further deteriorated from JP¥15.16 loss in 3Q 2022). Revenue: JP¥574.0m (up 59% from 3Q 2022). Net loss: JP¥1.70b (loss widened 106% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • Feb 163-D Matrix, Ltd. to Report Q3, 2023 Results on Mar 17, 20233-D Matrix, Ltd. announced that they will report Q3, 2023 results on Mar 17, 2023
Reported Earnings • Dec 15Second quarter 2023 earnings released: EPS: JP¥2.42 (vs JP¥9.09 loss in 2Q 2022)Second quarter 2023 results: EPS: JP¥2.42 (up from JP¥9.09 loss in 2Q 2022). Revenue: JP¥561.0m (up 87% from 2Q 2022). Net income: JP¥144.0m (up JP¥589.0m from 2Q 2022). Profit margin: 26% (up from net loss in 2Q 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent External Director Kazuya Shimamura was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 093-D Matrix, Ltd. to Report Q2, 2023 Results on Dec 13, 20223-D Matrix, Ltd. announced that they will report Q2, 2023 results on Dec 13, 2022
お知らせ • Oct 193-D Matrix, Ltd. announced that it has received ¥2.059835568 billion in funding from CVI Investments, Inc.On October 17, 2022, 3-D Matrix, Ltd. closed the transaction.
お知らせ • Oct 013-D Matrix, Ltd. announced that it expects to receive ¥2.059835568 billion in funding from CVI Investments, Inc.3-D Matrix, Ltd. announced a private placement of 6th unsecured convertible bonds, with a face of ¥100 each, at a price of ¥100 per corporate bond for gross proceeds of ¥2,050,000,000 with stock acquisition rights and 55,256 33rd stock acquisition rights at a price of ¥178 for gross proceeds of ¥9,835,568; for an aggregate gross proceeds of ¥2,059,835,568 on September 30, 2022. The transaction will include participation from returning investor CVI Investments, Inc. The funding will be raised through third-party allotment. The bonds will be convertible at an initial conversion price of ¥371 into 5,525,606 shares from October 17, 2025 to April 17, 2026 and matures on October 22, 2026. The bonds carry interest rate of 2%. The bonds are redeemable. The exercise period for 33rd stock acquisition rights is from October 18, 2022 to October 18, 2027. They carry an initial exercise price of ¥371 each. The transaction has been approved by the board of directors of directors. The transaction is expected to close on October 17, 2022.
Reported Earnings • Sep 16First quarter 2023 earnings released: JP¥9.24 loss per share (vs JP¥17.54 loss in 1Q 2022)First quarter 2023 results: JP¥9.24 loss per share (improved from JP¥17.54 loss in 1Q 2022). Revenue: JP¥423.0m (up 24% from 1Q 2022). Net loss: JP¥524.0m (loss narrowed 34% from 1Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • Aug 033-D Matrix, Ltd. to Report Q1, 2023 Results on Sep 14, 20223-D Matrix, Ltd. announced that they will report Q1, 2023 results on Sep 14, 2022
Reported Earnings • Aug 03Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: JP¥37.19 loss per share (up from JP¥49.64 loss in FY 2021). Revenue: JP¥1.51b (up 47% from FY 2021). Net loss: JP¥1.89b (loss narrowed 5.9% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 29%. Over the next year, revenue is forecast to grow 79%, compared to a 256% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • Jun 163-D Matrix, Ltd., Annual General Meeting, Jul 28, 20223-D Matrix, Ltd., Annual General Meeting, Jul 28, 2022.
Reported Earnings • Jun 15Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: JP¥37.19 loss per share (up from JP¥49.64 loss in FY 2021). Revenue: JP¥1.51b (up 47% from FY 2021). Net loss: JP¥1.89b (loss narrowed 5.9% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 29%. Over the next year, revenue is forecast to grow 79%, compared to a 546% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
お知らせ • May 133-D Matrix, Ltd. to Report Fiscal Year 2022 Results on Jun 14, 20223-D Matrix, Ltd. announced that they will report fiscal year 2022 results on Jun 14, 2022
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent External Director Kazuya Shimamura was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 133-D Matrix, Ltd. announced that it expects to receive ¥1.7650936 billion in funding from CVI Investments, Inc.3-D Matrix, Ltd. announced a private placement of approximately 17,650,936 5th unsecured convertible bonds, with a face of JPY 100 each, at a price of JPY 100 per corporate bond with 40 units of stock acquisition rights for gross proceeds of JPY 1,765,093,600 and 31st stock acquisition rights on April 11, 2022. The funding will be raised through third-party allotment. The transaction is expected to close on April 27, 2022. The stock acquisition rights will be convertible at a initial conversion price of JPY 441 into 4,002,479 shares. The transaction will include participation from returning investor CVI Investments, Inc. The bonds carry interest rate of 2% and have a redemption date of June 5, 2026. The application period for 31st stock acquisition rights is on April 27, 2022. They carry an initial exercise price of JPY 441 each. The transaction has been approved by the board of directors of directors.
Reported Earnings • Mar 16Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: JP¥15.16 loss per share (down from JP¥11.52 loss in 3Q 2021). Revenue: JP¥360.0m (up 55% from 3Q 2021). Net loss: JP¥828.0m (loss widened 73% from 3Q 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 8.2%. Over the next year, revenue is forecast to grow 139%, compared to a 2,909% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Reported Earnings • Dec 17Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: JP¥9.09 loss per share (up from JP¥16.66 loss in 2Q 2021). Revenue: JP¥300.0m (up 14% from 2Q 2021). Net loss: JP¥445.0m (loss narrowed 35% from 2Q 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 8.2%. Earnings per share (EPS) missed analyst estimates by 8.2%. Over the next year, revenue is forecast to grow 135%, compared to a 3,108% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Sep 18First quarter 2022 earnings released: JP¥17.54 loss per share (vs JP¥11.16 loss in 1Q 2021)The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: JP¥340.0m (up 63% from 1Q 2021). Net loss: JP¥797.0m (loss widened 95% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
お知らせ • Aug 283-D Matrix, Ltd. announced that it has received ¥2.609 billion in funding from CVI Investments, Inc.On August 27, 2021, 3-D Matrix, Ltd. closed the transaction.
お知らせ • Aug 123-D Matrix, Ltd. announced that it expects to receive ¥2.609 billion in funding from CVI Investments, Inc.3-D Matrix, Ltd. announced a private placement of approximately 8,000,000 4th unsecured convertible bonds, with a face of JPY 100 each, at a price of JPY 100 per corporate bond with 40 units of stock acquisition rights for gross proceeds of JPY 800,000,000 and 65,000 30th stock acquisition rights for gross proceeds of JPY 14,430,000, for aggregate gross proceeds of JPY 2,609,000 on August 11, 2021. The funding will be raised through third-party allotment. The transaction is expected to close on August 27, 2021. The stock acquisition rights will be convertible at a initial conversion price of JPY 311 into 2,572,347 shares. The transaction will include participation from returning investor CVI Investments, Inc. The bonds carry no interest rate and have a redemption date of October 4, 2025. The application period for 30th stock acquisition rights is from August 30, 2021 to August 29, 2022. They carry an initial exercise price of JPY 280 each. The transaction has been approved by the board of directors of directors.
お知らせ • Aug 053-D Matrix, Ltd. (JASDAQ:7777) signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd.3-D Matrix, Ltd. (JASDAQ:7777) signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd. on August 3, 2021. As part of the transaction, 3-D Matrix, Ltd. will transfer patent and license to PURMX Therapeutics Co., Ltd.
Reported Earnings • Aug 03Full year 2021 earnings released: JP¥49.64 loss per share (vs JP¥103 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥1.02b (up 52% from FY 2020). Net loss: JP¥2.01b (loss narrowed 35% from FY 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 18Full year 2021 earnings released: JP¥49.64 loss per share (vs JP¥103 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥1.02b (up 52% from FY 2020). Net loss: JP¥2.01b (loss narrowed 35% from FY 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
分析記事 • Apr 223-D Matrix (TYO:7777) Is Carrying A Fair Bit Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Mar 18Third quarter 2021 earnings released: JP¥11.52 loss per share (vs JP¥22.05 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥233.0m (up 23% from 3Q 2020). Net loss: JP¥479.0m (loss narrowed 28% from 3Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
お知らせ • Mar 073-D Matrix, Ltd. to Report Q3, 2021 Results on Mar 16, 20213-D Matrix, Ltd. announced that they will report Q3, 2021 results on Mar 16, 2021
分析記事 • Feb 233-D Matrix's (TYO:7777) Shareholders Are Down 68% On Their SharesThe truth is that if you invest for long enough, you're going to end up with some losing stocks. But long term 3-D...
Is New 90 Day High Low • Dec 25New 90-day low: JP¥280The company is down 32% from its price of JP¥410 on 25 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.
Reported Earnings • Dec 17Second quarter 2021 earnings released: JP¥16.66 loss per shareThe company reported a solid second quarter result with improved revenues and control over expenses, though losses increased. Second quarter 2021 results: Revenue: JP¥263.0m (up 50% from 2Q 2020). Net loss: JP¥679.0m (loss widened 6.6% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Dec 08New 90-day low: JP¥339The company is down 14% from its price of JP¥395 on 09 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period.
お知らせ • Dec 053-D Matrix, Ltd. to Report Q2, 2021 Results on Dec 15, 20203-D Matrix, Ltd. announced that they will report Q2, 2021 results on Dec 15, 2020
お知らせ • Nov 113-D Matrix, Ltd. announced that it expects to receive ¥216.0702 million in funding from CVI Investments, Inc.3-D Matrix, Ltd. (JASDAQ:7777) announced that it has entered into purchase agreement to issue 561,700 shares at issue price of ¥356 per share for gross proceeds of ¥199,965,200, 55,000 27th stock acquisition rights at issue price of ¥291 per right for gross proceeds of ¥16,105,000, 10,000 28th stock acquisition rights at issue price of ¥10 per right for gross proceeds of ¥100,000; for an aggregate gross proceeds of ¥216,170,200 on November 10, 2020. The transaction includes participation from returning investor, CVI Investments, Inc. The company will raise money through third party allotment. The 27th stock acquisition rights can be exercisable to purchase 5,500,000 shares of the company at an exercise price of ¥356 per share and 28th stock acquisition rights can be exercise to purchase 1,000,000 shares of the company at an exercise price of ¥435 per share. The 27th stock acquisition rights can be exercised from November 27, 2020 to May 26, 2022 and 28th stock acquisition rights can be exercised from November 27, 2020 to November 26, 2024. The company incurred issuance expense of ¥25,000,000 in relation to the transaction. The transaction is expected to close on November 26, 2020. The transaction has been approved by the board of directors of the company.
Is New 90 Day High Low • Nov 01New 90-day low: JP¥378The company is down 3.0% from its price of JP¥389 on 03 August 2020. The Japanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.
お知らせ • Sep 043-D Matrix, Ltd. to Report Q1, 2021 Results on Sep 14, 20203-D Matrix, Ltd. announced that they will report Q1, 2021 results on Sep 14, 2020
